Clinical Trials · NCT01193244
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Enrollment
- 1,560
- Start date
- Oct 2010
- Locations
- 240 sites, 40 countries
- Primary endpoint
- Radiographic Progression-free Survival (rPFS)